Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMZA47Y)

Drug Name
Iomab-B Drug Info
Synonyms Iomab-B (TN)
Indication
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 3 [1]
Bone marrow transplantation QB63.6 Phase 3 [2]
Cross-matching ID
TTD Drug ID
DMZA47Y

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Leukocyte common antigen (PTPRC) TTUS45N PTPRC_HUMAN Not Available [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Leukocyte common antigen (PTPRC) DTT PTPRC 6.121 6.524 4.548 6.619
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Acute myeloid leukaemia
ICD Disease Classification 2A60
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Leukocyte common antigen (PTPRC) DTT PTPRC 5.86E-05 -0.26 -0.36
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT02665065) Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia (SIERRA). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of Actinium Pharmaceuticals.